PMV Pharmaceuticals, Inc. (PMVP)
- Previous Close
1.7100 - Open
1.7200 - Bid 1.7300 x 200
- Ask 1.7900 x 100
- Day's Range
1.6900 - 1.7650 - 52 Week Range
1.1750 - 9.7200 - Volume
334,030 - Avg. Volume
571,406 - Market Cap (intraday)
90.026M - Beta (5Y Monthly) 1.64
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4400 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.75
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
www.pmvpharma.comRecent News: PMVP
Performance Overview: PMVP
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PMVP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PMVP
Valuation Measures
Market Cap
90.03M
Enterprise Value
-99.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.40
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
1.26
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.17%
Return on Equity (ttm)
-29.24%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-68.96M
Diluted EPS (ttm)
-1.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
203.06M
Total Debt/Equity (mrq)
5.89%
Levered Free Cash Flow (ttm)
-32.94M